Search results

  1. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Recommendation ID NG188/2 Question What are the most clinically effective interventions (including social prescribing and structured community

  2. Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG683/1 Question Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus

  3. Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG682/1 Question Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate

  4. Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent but potentially serious adverse events: For people who need to lose weight in the short term for medical reasons, the evidence of efficacy is adequate to support the use of this procedure provided that special arrangements are in place for clinical governance, consent and audit.  Find out  what special arrangements mean on the NICE interventional procedures guidance page . For people who are aiming for long-term weight loss, the evidence on efficacy is inadequate in quantity and quality, so the procedure should only be used in the context of research.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG684/1 Question Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent

  5. Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis shows that this procedure can cause serious but well-recognised side effects. Evidence on its efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out what  only in research means on the NICE website .

    Recommendation ID IPG681/1 Question Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

  6. Develop and validate new and existing screening tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for post‑COVID‑19 syndrome, which are the most accurate at identifying post‑COVID‑19 syndrome in a UK population and what is their effectiveness in guiding management?

    Recommendation ID NG188/7 Question Develop and validate new and existing screening tools (including physical, psychological and

  7. NICE signs up to join the GetReal Institute

    NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.

  8. Starting with the end in mind - the Innovative Licensing and Access Pathway

    Launched in January, the new Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS. It is an exciting development that signals greater collaboration between the agencies involved and, we hope, should bring significant benefits to patients.

  9. NICE welcomes appointment of six new Board members

    NICE is delighted with today’s (15 March) announcement from the Department of Health & Social Care appointing six new non-executive directors to its Board following their approval by the Secretary of State.